{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:47:42Z","timestamp":1792320462387,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40268-024-00458-6","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T03:11:59Z","timestamp":1710385919000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6856-642X","authenticated-orcid":false,"given":"S. R. E.","family":"Laarhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H. M.","family":"Kerskes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Nijziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. A.","family":"van Wensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"12","key":"458_CR1","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","volume":"42","author":"SM Swaney","year":"1998","unstructured":"Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42(12):3251\u20135. https:\/\/doi.org\/10.1128\/AAC.42.12.3251.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"458_CR2","first-page":"1136","volume":"29","author":"J Slatter","year":"2001","unstructured":"Slatter J, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14 C]linezolid to healthy human subjects. Am Soc Pharmacol Exp Ther. 2001;29(8):1136\u201345.","journal-title":"Am Soc Pharmacol Exp Ther"},{"issue":"4","key":"458_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1345\/aph.1C361","volume":"37","author":"WB Bernstein","year":"2003","unstructured":"Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517\u201320. https:\/\/doi.org\/10.1345\/aph.1C361.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"458_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","volume":"44","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.010.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"458_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00228-013-1585-6","volume":"70","author":"AP Cossu","year":"2014","unstructured":"Cossu AP, Musu M, Mura P, De Giudici LM, Finco G. Linezolid-induced thrombocytopenia in impaired renal function: Is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol. 2014;70(1):23\u20138. https:\/\/doi.org\/10.1007\/s00228-013-1585-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"458_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4140\/TCP.n.2012.504","volume":"27","author":"S Lam","year":"2012","unstructured":"Lam S. Linezolid-associated thrombocytopenia. Consult Pharm. 2012;27(7):504\u20138. https:\/\/doi.org\/10.4140\/TCP.n.2012.504.","journal-title":"Consult Pharm"},{"issue":"11","key":"458_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5414\/CNP68327","volume":"68","author":"L Esposito","year":"2007","unstructured":"Esposito L, Kamar N, Guilbeau-Frugier C, Mehrenberger M, Modesto A, Rostaing L. Linezolid-induced interstitial nephritis in a kidney-transplant patient. Clin Nephrol. 2007;68(11):327\u20139. https:\/\/doi.org\/10.5414\/CNP68327.","journal-title":"Clin Nephrol"},{"issue":"10","key":"458_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/1756-185X.13683","volume":"22","author":"RV Navarroza","year":"2019","unstructured":"Navarroza RV, Zamora LD, Navarra SV. Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. Int J Rheum Dis. 2019;22(10):1933\u20136. https:\/\/doi.org\/10.1111\/1756-185X.13683.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"458_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2169\/internalmedicine.54.2292","volume":"54","author":"Y Tsuji","year":"2015","unstructured":"Tsuji Y, et al. Treatment of mediastinitis due to methicillin-resistant staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose. Intern Med. 2015;54(2):235\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.54.2292.","journal-title":"Intern Med"},{"issue":"4","key":"458_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1179\/1973947812Y.0000000014","volume":"24","author":"N Berenguer","year":"2012","unstructured":"Berenguer N, Ferr\u00e1ndez O, Barbosa F, Urbina O, Espona M, Grau S. Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis. J Chemother. 2012;24(4):226\u20138. https:\/\/doi.org\/10.1179\/1973947812Y.0000000014.","journal-title":"J Chemother"},{"issue":"1","key":"458_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/00365548.2012.708783","volume":"45","author":"K Taguchi","year":"2013","unstructured":"Taguchi K, et al. A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency. Scand J Infect Dis. 2013;45(1):77\u201380. https:\/\/doi.org\/10.3109\/00365548.2012.708783.","journal-title":"Scand J Infect Dis"},{"key":"458_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00605-19","author":"RL Crass","year":"2019","unstructured":"Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00605-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1086\/498509","volume":"42","author":"V-C Wu","year":"2005","unstructured":"Wu V-C, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Infect Dis Soc Am. 2005;42:66\u201372. https:\/\/doi.org\/10.1086\/498509.","journal-title":"Infect Dis Soc Am"},{"issue":"3","key":"458_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jpids\/piu035","volume":"4","author":"SJ Jones","year":"2015","unstructured":"Jones SJ, Nichols KR, DeYoung HL, Cox EG, Knoderer CA. Linezolid-associated thrombocytopenia in children with renal impairment. J Pediatric Infect Dis Soc. 2015;4(3):272\u20135. https:\/\/doi.org\/10.1093\/jpids\/piu035.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"4","key":"458_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","volume":"28","author":"Y-H Lin","year":"2006","unstructured":"Lin Y-H, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345\u201351. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.04.017.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"458_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7399\/fh.2015.39.6.8305","volume":"39","author":"L Moraza","year":"2015","unstructured":"Moraza L, Leache L, Aquerreta I, Ortega A. Linezolid-induced haematological toxicity. Farm Hosp. 2015;39(6):320\u201332. https:\/\/doi.org\/10.7399\/fh.2015.39.6.8305.","journal-title":"Farm Hosp"},{"issue":"2","key":"458_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bcp.14965","volume":"88","author":"C Shi","year":"2022","unstructured":"Shi C, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):464\u201375. https:\/\/doi.org\/10.1111\/bcp.14965.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"458_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","volume":"22","author":"H Kawasuji","year":"2021","unstructured":"Kawasuji H, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol. 2021;22(1):13. https:\/\/doi.org\/10.1186\/s40360-021-00479-w.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"458_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.htct.2019.07.004","volume":"42","author":"LS Lima","year":"2020","unstructured":"Lima LS, Brito ECA, Mattos K, Parisotto EB, Perdomo RT, Weber SS. A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil. Hematol Transfus Cell Ther. 2020;42(3):230\u20137. https:\/\/doi.org\/10.1016\/j.htct.2019.07.004.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"4","key":"458_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","volume":"36","author":"R Hirano","year":"2014","unstructured":"Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36(4):795\u20139. https:\/\/doi.org\/10.1007\/s11096-014-9961-6.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"458_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","volume":"73","author":"C Chen","year":"2012","unstructured":"Chen C, et al. Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195\u2013206. https:\/\/doi.org\/10.1016\/j.curtheres.2012.07.002.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"10","key":"458_CR22","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/j.clinthera.2009.10.017","volume":"31","author":"T Niwa","year":"2009","unstructured":"Niwa T, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126\u201333. https:\/\/doi.org\/10.1016\/j.clinthera.2009.10.017.","journal-title":"Clin Ther"},{"key":"458_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.12659\/AJCR.911362","volume":"19","author":"B Xiao","year":"2018","unstructured":"Xiao B, Deng P, Jin H, Wang H, Cao Y. Lactic acidosis and thrombocytopenia associated with linezolid therapy: a case report. Am J Case Reports. 2018;19:1117\u201320. https:\/\/doi.org\/10.12659\/AJCR.911362.","journal-title":"Am J Case Reports"},{"key":"458_CR24","unstructured":"\u201cSPC Linezolid.\u201d Accessed: Jan. 23, 2023. Available: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h115279_smpc.pdf"},{"issue":"9","key":"458_CR25","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","volume":"47","author":"ME Brier","year":"2003","unstructured":"Brier ME, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775\u201380. https:\/\/doi.org\/10.1128\/AAC.47.9.2775-2780.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00027-20","author":"E Souza","year":"2020","unstructured":"Souza E, Crass RL, Felton J, Hanaya K, Pai MP. Accumulation of major linezolid metabolites in patients with renal impairment. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.00027-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg248","author":"AP MacGowan","year":"2003","unstructured":"MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003. https:\/\/doi.org\/10.1093\/jac\/dkg248.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"458_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","volume":"36","author":"K Matsumoto","year":"2010","unstructured":"Matsumoto K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36(2):179\u201381. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.02.019.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"458_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10156-010-0080-6","volume":"17","author":"Y Tsuji","year":"2011","unstructured":"Tsuji Y, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17(1):70\u20135. https:\/\/doi.org\/10.1007\/s10156-010-0080-6.","journal-title":"J Infect Chemother"},{"issue":"6","key":"458_CR30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/MAJ.0b013e318218cf18","volume":"342","author":"Y Hiraki","year":"2011","unstructured":"Hiraki Y, Tsuji Y, Matsumoto K, Morita K, Kamimura H, Karube Y. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci. 2011;342(6):456\u201360. https:\/\/doi.org\/10.1097\/MAJ.0b013e318218cf18.","journal-title":"Am J Med Sci"},{"issue":"9","key":"458_CR31","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","volume":"68","author":"Y Nukui","year":"2013","unstructured":"Nukui Y, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128\u201333. https:\/\/doi.org\/10.1093\/jac\/dkt133.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"458_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","volume":"41","author":"D Cattaneo","year":"2013","unstructured":"Cattaneo D, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.02.020.","journal-title":"Int J Antimicrob Agents"},{"key":"458_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050496","author":"H Kawasuji","year":"2021","unstructured":"Kawasuji H, et al. Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients. Antibiotics Basel. 2021. https:\/\/doi.org\/10.3390\/antibiotics10050496.","journal-title":"Antibiotics Basel"},{"issue":"7","key":"458_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/atm.2020.03.207","volume":"8","author":"J Fang","year":"2020","unstructured":"Fang J, et al. Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?\u2014Experience from a prospective observational study. Ann Transl Med. 2020;8(7):493\u2013493. https:\/\/doi.org\/10.21037\/atm.2020.03.207.","journal-title":"Ann Transl Med"},{"issue":"4","key":"458_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcpt.12797","volume":"121","author":"F Pea","year":"2017","unstructured":"Pea F, Cojutti PG, Baraldo M. A 10-year experience of Therapeutic Drug Monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: Is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121(4):303\u20138. https:\/\/doi.org\/10.1111\/bcpt.12797.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"458_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","volume":"48","author":"D Cattaneo","year":"2016","unstructured":"Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48(6):728\u201331. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.08.023.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"458_CR37","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s10096-017-2960-5","volume":"36","author":"J Gonz\u00e1lez-Del Castillo","year":"2017","unstructured":"Gonz\u00e1lez-Del Castillo J, et al. Predictive score of haematological toxicity in patients treated with linezolid. Eur J Clin Microbiol Infect Dis. 2017;36(8):1511\u20137. https:\/\/doi.org\/10.1007\/s10096-017-2960-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"458_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi GW, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228\u201334. https:\/\/doi.org\/10.1111\/bcpt.13123.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"458_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","volume":"42","author":"GG Rao","year":"2020","unstructured":"Rao GG, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83\u201392. https:\/\/doi.org\/10.1097\/FTD.0000000000000710.","journal-title":"Ther Drug Monit"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00458-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T04:02:46Z","timestamp":1713844966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00458-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00458-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"22 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The participants have consented to the submission of the case report to the journal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The original data is available on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material Code"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by SRE Laarhuis. The first draft of the manuscript was written by SRE Laarhuis and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}